-
公开(公告)号:EP2632895A4
公开(公告)日:2015-12-16
申请号:EP11835398
申请日:2011-10-27
申请人: MERCK CANADA INC
IPC分类号: C07C311/41 , A61K31/27 , A61K31/428 , A61P31/18 , C07C311/29 , C07D277/62 , C07D413/12 , C07D417/12
CPC分类号: C07C311/39 , C07C311/29 , C07C311/41 , C07D277/62 , C07D413/12 , C07D417/12
摘要: Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
摘要翻译: 公开了其中R1,R2,R3A,R3B,R4A,R4B,R5A,R5B,R6A,R6B,R7,R8和R9在本文中定义的式I化合物。 式I所包括的化合物包括可以在体内代谢为HIV蛋白酶抑制剂的HIV蛋白酶抑制剂和其它化合物的化合物。 化合物及其药学上可接受的盐可用于预防或治疗HIV感染以及预防,治疗或延迟艾滋病的发病。 化合物及其盐可以用作药物组合物中的成分,任选地与其它抗病毒剂,免疫调节剂,抗生素或疫苗组合使用。
-
公开(公告)号:EP2771332A4
公开(公告)日:2015-05-06
申请号:EP12843729
申请日:2012-10-26
申请人: MERCK CANADA INC
IPC分类号: C07D333/20 , A61K31/33 , A61K31/381 , A61K31/404 , A61K31/42 , A61K31/4245 , A61K31/428 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/4725 , A61K31/4985 , A61P31/18 , C07D277/28 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
CPC分类号: C07D333/20 , C07B59/002 , C07D277/28 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
-